Wells Fargo & Company Amryt Pharma PLC Transaction History

Wells Fargo & Company

  • $407 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
SELL
$7.0 - $14.77 $97,321 - $205,347
-13,903 Reduced 4.74%
279,495 $4.08 Million
Q4 2022

Feb 13, 2023
BUY
$6.68 - $7.58 $422,202 - $479,086
63,204 Added 27.46%
293,398 $2.14 Million
Q3 2022

Nov 14, 2022
BUY
$6.8 - $8.01 $1.34 Million - $1.57 Million
196,569 Added 584.59%
230,194 $1.59 Million
Q4 2021

Feb 14, 2022
SELL
$9.44 - $12.24 $5,701 - $7,392
-604 Reduced 1.76%
33,625 $363,000
Q3 2021

Nov 15, 2021
BUY
$9.63 - $12.47 $329,625 - $426,835
34,229 New
34,229 $412,000

Others Institutions Holding AMYT

# of Institutions
5
Shares Held
142K
Call Options Held
0
Put Options Held
0
View Full List

About Amryt Pharma plc

AMYT Quotes by TradingView
  • Ticker AMYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 64,177,000
  • Description
  • Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with ...
More about AMYT
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email